BioSpace News Archive

The increasing population and pervasiveness of different diseases are leading to the requirement of advanced healthcare facilities.

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products.

J INTS BIO announced that it held its 1st International Advisory Board Meeting for its Novel Oral 4th Generation EGFR-TKI ‘JIN-A02' on the sideline of the 2022 IASLC World Conference on Lung Cancer held in Vienna, Austria, on 7th August.

The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, announced that EMA has validated the Marketing Authorization Application for elacestrant, a selective estrogen receptor degrader, for patients with ER+/HER2- advanced or metastatic breast cancer.

Wilmington, Delaware, United States, Transparency Market Research Inc. – The operating rooms always require technologically advanced and specialized lighting systems, as these systems play an important role for a successful operation.

SpringWorks Therapeutics, Inc. announced that data from the Phase 3 DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, will be presented as a late-breaking oral presentation at the European Society for Medical Oncology Congress 2022.

SciSparc Ltd. announced the full exercise of 3,211,100 pre-funded warrants that were issued as part of a private placement financing for gross proceeds of $10 million, which closed on June 1, 2022.

Jaguar Health, Inc.today announced that on August 18, 2022 the Company received formal notice that the Listing Qualifications Staff of The Nasdaq Stock Market LLC has granted Jaguar an additional 180-day grace period, through February 13, 2023, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market.

Aarvik Therapeutics announced the recent publication by Sachdev Sidhu, Ph.D., Co-founder of Aarvik Therapeutics, and his colleagues of a study validating the novel tetravalent antibody platform that forms a core component of innovation at Aarvik.

Verismo Therapeutics today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) requesting approval to initiate its first-in-human Phase 1 clinical trial of SynKIR-110 in patients with mesothelin-expressing ovarian cancer, mesothelioma and cholangiocarcinoma.